IFRX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

29.50K

-76.18%

-0.138

+71.88%

26.17K

-6330.95%

-0.123

-5.13%

-0.127

-39.68%

Estimates Revision

The market is revising Downward the revenue expectations for InflaRx N.V. (IFRX) for FY2025, with the revenue forecasts being adjusted by -31.83% over the past three months. During the same period, the stock price has changed by -19.84%.

Revenue Estimates for FY2025

Revise Downward

-31.83%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+11.62%

In Past 3 Month

Stock Price

Go Down

-19.84%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast IFRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IFRX is 11.14 USD with a low forecast of 2.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.986

Low

2.00

Averages

11.14

High

24.00

Current: 0.986

Low

2.00

Averages

11.14

High

24.00

Leerink

Outperform -> Market Perform

downgrade

2025-12-03

Reason

Leerink

Price Target

2025-12-03

downgrade

Outperform -> Market Perform

Reason

Leerink downgraded InflaRx to Market Perform from Outperform with a $2 price target.

Leerink

Joseph Schwartz

Outperform -> Market Perform

downgrade

$5 -> $2

2025-12-03

Reason

Leerink

Joseph Schwartz

Price Target

$5 -> $2

2025-12-03

downgrade

Outperform -> Market Perform

Reason

Leerink analyst Joseph Schwartz downgraded InflaRx to Market Perform from Outperform with a price target of $2, down from $5. InflaRx delivered unexpectedly positive Phase 2a data for INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria, with the HS results looking compelling enough to justify a Phase 2b trial, the analyst tells investors in a research note. Despite management's view that its EUR 44.4M cash balance can fund operations into 2027, further financing appears likely and could be notably dilutive at the current valuation.

Raymond James

Ryan Deschner

Outperform

maintain

$2 -> $9

2025-11-11

Reason

Raymond James

Ryan Deschner

Price Target

$2 -> $9

2025-11-11

maintain

Outperform

Reason

Raymond James analyst Ryan Deschner raised the firm's price target on InflaRx to $9 from $2 and keeps an Outperform rating on the shares. Inflarx reported "strong" early efficacy and safety data from their oral C5aR inhibitor INF904 in Hidradenitis Suppurative patients in a Phase 2a autoimmune disease basket study, the analyst tells investors in a research note. The response of HS patients at 4 weeks is very positive, given competitive levels of HiSCR response were seen at 4 weeks, further increasing for at least four more weeks post-treatment, and Raymond James believes there is ample room for an oral drug with a novel mechanism in the HS market.

Oppenheimer

Andreas Argyrides

Outperform

maintain

$3 -> $7

2025-11-11

Reason

Oppenheimer

Andreas Argyrides

Price Target

$3 -> $7

2025-11-11

maintain

Outperform

Reason

Oppenheimer analyst Andreas Argyrides raised the firm's price target on InflaRx to $7 from $3 and keeps an Outperform rating on the shares following positive results from the Phase 2a basket study of INF904 in hidradenitis suppurative and chronic spontaneous urticaria. The firm sees INF904 emerging as a best-in-class oral therapy with favorable safety and a superior PK/PD profile vs. avacopan. The robust results derisk INF904's profile, warranting further development in both indications, Oppenheimer adds.

Cantor Fitzgerald

NULL -> Overweight

maintain

$3 -> $8

2025-11-11

Reason

Cantor Fitzgerald

Price Target

$3 -> $8

2025-11-11

maintain

NULL -> Overweight

Reason

Cantor Fitzgerald raised the firm's price target on InflaRx to $8 from $3 and keeps an Overweight rating on the shares. InflaRx's C5aR inhibitor is looking good, and the company should pursue the efficacy signal in a larger, longer Phase 2B hidradenitis suppurative study, the analyst tells investors in a research note.

Guggenheim

Buy

upgrade

$10 -> $22

2025-11-10

Reason

Guggenheim

Price Target

$10 -> $22

2025-11-10

upgrade

Buy

Reason

Guggenheim raised the firm's price target on InflaRx to $22 from $10 and keeps a Buy rating on the shares after the company announced topline data from a Phase 2a basket study exploring INF904 in hidradenitis suppurativa and chronic spontaneous urticaria. The firm raised its view of the odds of success in HS to 65% from 30% following the data and models peak HS sales of about $1.5B.

Valuation Metrics

The current forward P/E ratio for InflaRx NV (IFRX.O) is -1.73, compared to its 5-year average forward P/E of -2.42. For a more detailed relative valuation and DCF analysis to assess InflaRx NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.42

Current PE

-1.73

Overvalued PE

-1.35

Undervalued PE

-3.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.12

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.98

Undervalued EV/EBITDA

-4.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1905.20

Current PS

1283.74

Overvalued PS

9035.19

Undervalued PS

-5224.80

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 425.33% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

IFRX News & Events

Events Timeline

No data

News

4.5

11-10NASDAQ.COM

Most Active Stocks in Pre-Market Trading on November 10, 2025: IFRX, GREE, IPHA, TSLL, SQQQ, NVDA, PFE, BBAI, OSCR, IONQ, HLN, THS

2.0

11-10Benzinga

Viasat Shares Rise Approximately 13%; Check Out 20 Stocks Making Moves in Premarket Trading

9.5

11-10NASDAQ.COM

Biotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours

People Also Watch

Frequently Asked Questions

What is InflaRx NV (IFRX) stock price today?

The current price of IFRX is 0.986 USD — it has decreased -6.1 % in the last trading day.

What is InflaRx NV (IFRX)'s business?

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.

What is the price predicton of IFRX Stock?

What is InflaRx NV (IFRX)'s revenue for the last quarter?

InflaRx NV revenue for the last quarter amounts to 23.83K USD, decreased -80.75 % YoY.

What is InflaRx NV (IFRX)'s earnings per share (EPS) for the last quarter?

InflaRx NV. EPS for the last quarter amounts to -0.18 USD, decreased -40.00 % YoY.

What changes have occurred in the market's expectations for InflaRx NV (IFRX)'s fundamentals?

How many employees does InflaRx NV (IFRX). have?

InflaRx NV (IFRX) has 74 emplpoyees as of December 15 2025.

What is InflaRx NV (IFRX) market cap?

Today IFRX has the market capitalization of 71.13M USD.